Medivir AB

Showing: 1 - 2 of 2 Articles

TNG348 First Patient Dosing - Medivir Milestone

Pharmaceuticals News

Medivir´s licensee, Tango Therapeutics, has dosed the first patient with TNG348, a novel USP1 inhibitor, in a phase 1/2 clinical study

Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer …

vinay January 4, 2024January 4, 2024

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer …

vinay September 1, 2023September 2, 2023